Good afternoon, and welcome to the Revenio Group Q3 earnings call. My name is Jouni Toijala, and I'm the group CEO. And we have here as well. Uh, Robin Pulkkinen, our CFO. Today, I'm going to start by going through the highlights for Q3. So, a bit of numbers then, highlights from the business and products. Then Robin is going to go through the financials in more detail and then finish up with the shareholders and reiterate the financial guidance.
So, let's jump to Q3. So, it was a good quarter in terms of organic sales growth for us. Net sales reached 23.9 million, an increase of 8.9% from last year, which was at 22 million. And it should be noted that we experienced significant currency headwinds from the US dollar to euro exchange rate. So, if you look at the growth from the currency-adjusted point of view, Q3 growth for July to September was actually 15.1% in operating profit, accounting for 23% of the net sales. So, $5.5 million, down from $6 million last year. And here, perhaps a couple of comments related to profitability.
So we got the headwind effects, roughly 10. €9 million. So, roughly a bit more than 50% actually goes through the EBITDA line as well. And then this was a really good quarter for us.
What comes to launching the new product. So we have a new tonometer, the iCare ST500, now out. Then we have the TONOVET Pro, also a new tonometer. We have been spending quite a lot of additional marketing money for the global launches of these products. But Robin is going to cover in more detail the cost side in his presentation and net cash flow from operations was 2.9 million, down from 5.6 million. But if we then look at the whole January to September highlights from the numbers perspective, we see extremely strong cash flow: 14.1 million, up from 5.6 million. And if we look at the sales growth for the first nine months. So, we are currently at 5%. And if looking at it from the guidance perspective. So, currency-adjusted growth on the sales side is 8.99%. But, if we jump next to the business highlights for Q3 2024. It was an extremely good quarter for us from the product perspective and from the regulatory approval perspective. A couple of comments related to that one. So, if we look at the sales in general, the sales of fundus imaging devices saw double-digit growth year on year. And again, the main growth products were the iCare EIDON family, and also the iCare DRSplus from the tonometry side had a good quarter as well. iCare HOME2 was actually one of the highest growing devices from the tonometer perspective, and from the imaging product portfolio. The iCare IC200 is growing well, and the newly launched iCare TONOVET Pro is getting extremely good traction. And of course, probes have been showing particularly strong performance in terms of growth as well. Then, positive news from China. So, we got the approval for iCare EIDON in China. Also the iCare IC200 Quick Measure. The tonometry feature, of course, along with the hardware, was then approved and received marketing authorization in China. So, this is actually really good news. These projects tend to take time. So as an example in the iCare case, we started the project already almost three years ago. And these projects are really, really time-consuming. So now we have a really good product portfolio available in China. So that's a plus. That's a plus. Then the Tonometers as well. So that's extremely good news for the future. And then there was also news during Q3 from the AI perspective. So we acquired a Dutch company called Thirona Retina. And the logic there was to get the assets on the AI platform. So we have been working with Thirona for a long time in the context of retina screening. So meaning together with the Iluma and iCare DRSplus. Plus, this enables us to now own the assets. We have the freedom to decide the business model, have a better margin, and in this context, nothing is going to change. So we are going to work with other AI players. Plus, we are going to guarantee that the support from Thirona Retina is going to continue. Also for other players like Topcon, like Canon, etc. , with whom they are working. So. So there is no plan to change this one at all. Then, in addition to having and using a Thirona Retina B.V. From a clinical decision support perspective, another rationale for the acquisition was that AI is increasingly gaining importance within the device and across its various functions. So now we have skills and capabilities also in-house for that one and for future development of the devices, and then not so good news from the CMS perspective, i.e.
The reimbursement code for the hardware for the iCare HOME2. So the decision was not to grant the durable medical equipment reimbursement code for iCare HOME2. And the reason was that you already have a good set of codes which you and your doctors are able to use. So the codes currently are codes for training, renting the device out, telehealth and remote monitoring, and data analysis. So that was the logic. So what does that mean for us. So we are going to continue the work around those codes and still want to remind everybody that if we look to Q3. So iCare HOME2 was the highest growing product segment for us. Then, we also launched the iCare ST500 slit lamp-mounted tonometer during Q3. And this is actually the continuation of the things that we said on April 1st, 2020, in our CMD. And I'm sure somebody remembers from the call audience that we said the long-term goal for us in tonometry is to make rebound technology the gold standard, replacing the Goldmann tonometer, which is more than 70 years old. So, this also partly answers that question. So what we are going to gain from the slit lamp mounted tonometer is that we haven't had a fully blown product portfolio for all patient workflows. So the patients who are going to undergo slit lamp examination. Mainly, Goldmann tonometers have been used to measure the IOP. So now we have a product for that one, and it fully complements our other rebound tonometers, iCare IC100, iCare IC200, and HOME. Then another important part is that if we think about the Goldmann assay, a method of measuring the IOP, it's not fully reliable. So, if you measure the patient at the clinic with the Goldmann tonometer and then, as an example, with iCare HOME2 at home, you get unreliable measurements in most cases, or at least not repeatable if you use the Goldmann. So now we have clinical proof that the entire platform, whether you measure the IOP with iCare IC100, iCare IC200, iCare HOME2, or test the ST500, is fully repeatable and completely comparable. So it's going to improve. Then, the patient care improves from that perspective. So, so, really good. And then perhaps thirdly I have to mention that this is not only the ST500. So, what is inside the device. It's totally new. So we have a totally new hardware platform inside the device, which we are going to use in the forthcoming new tonometers in years to come. A very significant product for us if we think of it from the long-term perspective.
Then we also got the timing right. Product is good to go. We already have orders in. We are able to produce it. We are able to ship. At the same time, we have FDA clearance. Plus, we have the CE mark for the device. So from that perspective, it's really good news and we're good to go. So let's switch gears and move to the financial side. So, over to you, Robin. Thanks, Jouni.